7,851 reports of this reaction
5.7% of all POMALIDOMIDE reports
#1 most reported adverse reaction
PLASMA CELL MYELOMA is the #1 most commonly reported adverse reaction for POMALIDOMIDE, manufactured by Celgene Corporation. There are 7,851 FDA adverse event reports linking POMALIDOMIDE to PLASMA CELL MYELOMA. This represents approximately 5.7% of all 136,988 adverse event reports for this drug.
POMALIDOMIDE has an overall safety score of 88 out of 100. Patients taking POMALIDOMIDE who experience plasma cell myeloma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLASMA CELL MYELOMA is moderately reported among POMALIDOMIDE users, representing a notable but not dominant share of adverse events.
In addition to plasma cell myeloma, the following adverse reactions have been reported for POMALIDOMIDE:
The following drugs have also been linked to plasma cell myeloma in FDA adverse event reports:
PLASMA CELL MYELOMA has been reported as an adverse event in 7,851 FDA reports for POMALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLASMA CELL MYELOMA accounts for approximately 5.7% of all adverse event reports for POMALIDOMIDE, making it one of the most commonly reported side effect.
If you experience plasma cell myeloma while taking POMALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.